Favipiravir was initially developed as an antiviral drug against influenza and is currently
used in clinical trials against severe acute respiratory syndrome coronavirus-2 (SARS-CoV …

Background The global research community has made considerable progress in therapeutic
and vaccine research during the COVID-19 pandemic. Several therapeutics have been …

The continued sustained threat of the SARS-CoV-2 virus world-wide, urgently calls for far-
reaching effective therapeutic strategies for treating this emerging infection. Accordingly, this …

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
developed into an unprecedented global pandemic. Nucleoside analogs, such as …

Introduction. The emergence of SARS-CoV-2 has taken humanity off guard. Following an
outbreak of SARS-CoV in 2002, and MERS-CoV about 10 years later, SARS-CoV-2 is the …

Since the outbreak emerged in November 2019, no effective drug has yet been found
against SARS-CoV-2. Repositioning studies of existing drug molecules or candidates are …

Our study was motivated by the urgent need to develop or improve antivirals for effective
therapy targeting RNA viruses. We hypothesized that analogues of favipiravir (FVP), an …

Abstract Coronavirus diseases 2019 (COVID-19) are seriously affecting human health all
over the world. Nucleotide inhibitors have promising results in terms of its efficacy against …

The detrimental effect of coronavirus disease 2019 (COVID-19) pandemic has manifested
itself as a global crisis. Currently, no specific treatment options are available for COVID-19 …

The rapid spread of the virus, the surge in the number of deaths, and the unavailability of
specific SARS-CoV-2 drugs thus far necessitate the identification of drugs with anti-COVID …